Nestlé Health Science to develop new therapy to treat ulcerative colitis Mittwoch, 16. September 2015 - 14:07

Nestlé Health Science has entered into a license agreement with Lipid Therapeutics for exclusive rights to develop and commercialise LT-02 - a new therapeutic approach that has shown success in treating mild-to-moderate ulcerative colitis.

Nestlé Health Science's rights to LT-02 will be global, except for Europe and Australia.

Read more: www.nestle.com/media/news/Nestle-Health-Science-therapy-ulcerative-colitis

More stories on our Nestlé News Feed: www.nestle.com/media

Media enquiries
Nestlé S.A. Vevey, Switzerland
Tel: +41 21 924 2200
Email: mediarelations@nestle.com

Follow Nestlé news
Twitter | Flickr | Facebook | YouTube